• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Qprotyn Inc

Monday, June 03, 2024
CP
Platform for Therapeutics
At Qprotyn our mission is to advance HILOPRO® - our unique and patented viscosity-reducing technology for antibodies which enables them to be injectable subcutaneously, without the use of hyaluronidase.   HILOPRO® viscosity-reduction technology will facilitate a formulation at a concentration greater than 250mg/mL at injectable viscosities < 20cP. This would enable 500mg+ doses in a standard 2cc syringe with a 27 gauge needle. Our platform technology works with mAbs and other protein biologics, using two common and safe excipients in combination, and was patented in 2020.
Qprotyn Inc
Company Website: http://www.qprotyn.com
Lead Product in Development: HILOPRO® viscosity-reduction technology for high-concentration mAbs enabliing them for subcutaneous delivery
Number Of Unlicensed Products (For Which You Are Seeking Partners): 3 Products for High-Concentration (>250mg/mL with viscosity <20cP) 1. Innovator Monoclonal Antibodies 2. High Concentration SC Biosimilars 3. SC Immunoglobulins

Company HQ City

Cambridge

Company HQ State

Massachusetts

Company HQ Country

United States

CEO/Top Company Official

Lynn Hartung - President, Qprotyn Inc.

Development Phase of Primary Product

Pre-Clinical
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS